Deoxyuridine

Deoxyuridine

SCHEMBL889540

O=c1ccn([C@H]2CC(O)[C@@H](CO)O2)c(=O)[nH]1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DUT P33316 3/20 0.64
TK1 P04183 3/20 0.62
LMNA P02545 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
SLC28A1 O00337 1/20 0.60
SLC28A2 O43868 1/20 0.60
SLC29A1 Q99808 1/20 0.60
SLC28A3 Q9HAS3 1/20 0.60
ALOX12 P18054 1/20 0.58
ADRA1A P35348 1/20 0.58
TK2 O00142 1/20 0.57
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
TSHR P16473 1/20 0.56
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deoxyuridine SCHEMBL9219261 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL2641582 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL114598 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL19841232 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL9708874 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL24512520 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL4847464 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL391224 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL9219265 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1
Deoxyuridine SCHEMBL28844 1.00 DUT (0.64) DUTTK1LMNASMN1; SMN2SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605713-B1 Contacting D-nucleic acids with a racemic mixture of the target molecule and allow for binding; producing L-nucleic acids; in vitro selection of DNA/RNA with high binding affinity and stability FURSTE JENS PETER (DE) 2003-08-12 US claimed
EP-1292313-A2 METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES Idenix (Cayman) Limited (KY) 2003-03-19 EP claimed
WO-2001091737-A2 METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES IDENIX (CAYMAN) LIMITED (KY) 2001-12-06 WO claimed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230010671-A1 PROTON ACTIVATED ATOMIC MEDICINE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2023-01-12 US disclosed
WO-2022099159-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2022-05-12 WO disclosed
US-20210214730-A1 CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF WAKE FOREST UNIVERSITY HEALTH SCIENCES 2021-07-15 US disclosed
US-20210196723-A1 Modulators of DUX4 for Regulation of Muscle Function SONIC MASTER LTD (VG) 2021-07-01 US disclosed
US-10933068-B2 Modulators of DUX4 for regulation of muscle function SONIC MASTER LIMITED (VG) 2021-03-02 US disclosed
US-20210024564-A1 PROTON ACTIVATED ATOMIC MEDICINE UNIVERSITY OF VIRGINIA 2021-01-28 US disclosed
EP-0717628-A1 NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY EMORY UNIVERSITY (US) 1996-06-26 EP disclosed
EP-0707481-A4 1996-05-29 EP disclosed
WO-1996014073-A1 TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY EMORY UNIVERSITY (US) 1996-05-17 WO disclosed
EP-0707481-A1 L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS YALE UNIVERSITY (US) 1996-04-24 EP disclosed
EP-0691981-A1 TUMOR TARGETING WITH L-ENANTIOMERIC OLIGONUCLEOTIDE CONJUGATES OF IMMUNOREAGENTS AND OF CHELATED RADIONUCLIDES THE WELLCOME FOUNDATION LIMITED (GB) 1996-01-17 EP disclosed
WO-1995015333-A1 NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS EMORY UNIVERSITY (US) 1995-06-08 WO disclosed
WO-1995007086-A1 NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY EMORY UNIVERSITY (US) 1995-03-16 WO disclosed
WO-1994027616-A1 L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS YALE UNIVERSITY (US) 1994-12-08 WO disclosed
WO-1994020523-A1 TUMOR TARGETING WITH L-ENANTIOMERIC OLIGONUCLEOTIDE CONJUGATES OF IMMUNOREAGENTS AND OF CHELATED RADIONUCLIDES THE WELLCOME FOUNDATION LIMITED (GB) 1994-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210196723-A1 Modulators of DUX4 for Regulation of Muscle Function DDX21, MBNL1, MECP2 DUT 568/4885TK1 2815/4885LMNA 1943/4885
US-10933068-B2 Modulators of DUX4 for regulation of muscle function DDX21, MBNL1, MECP2 DUT 556/4885TK1 2927/4885LMNA 2031/4885
US-20210024564-A1 PROTON ACTIVATED ATOMIC MEDICINE NUDT1, TK1, TK2 DUT 7/4885TK1 2/4885LMNA 1722/4885
US-20230010671-A1 PROTON ACTIVATED ATOMIC MEDICINE NUDT1, TK1, TK2 DUT 7/4885TK1 2/4885LMNA 1722/4885
US-20210214730-A1 CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF DCTD, CDA, DPYD DUT 6/4885TK1 198/4885LMNA 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.